News

The patent (U.S. Patent Number 10206894) covers methods for treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts. The new patent broadens the Company’s

Entrectinib has been granted priority review for the treatment of neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumors in adult and paediatric patients. The

The recommended dose of Keytruda for the adjuvant treatment of adult patients with melanoma is 200 mg administered as an intravenous infusion over 30 minutes every three weeks

“Pfizer is dedicated to increasing access to biosimilars for patients suffering from serious illnesses and helping create a more sustainable healthcare system,” said Andreas Penk, M.D., regional president,

Under the collaboration, the firms will evaluate the safety and tolerability of the combination therapy of Innovent’s Tyvyt (generic name: sintilimab injection), a fully human anti-programmed cell death

Under the agreement, Knight will initially lend Moksha8 up to US $25 million in working capital funding, of which US $10 million will be issued at closing. Knight

Additional work conducted on a drug exposure-response analysis showed a statistically significant response of BNC210 in treatment of PTSD symptoms, as measured by Clinician-Administered PTSD Scale (CAPS-5) at

PROVENGE (sipuleucel-T) was the first U.S. Food and Drug Administration (FDA)-approved immunotherapy made from a patient’s own immune cells. “We are pleased to work with Dendreon on this

The combination of Bavencia and Inlyta have significantly expanded median PFS by more than five months compared against Sutent (sunitinib) as a first-line treatment for patients with advanced